Xoma Could Initiate Pivotal Behcet’s Trial by Year-End 2011: Analyst
RBC Capital Markets said Xoma Ltd. (NASDAQ: XOMA) continues to make steady albeit measured progress toward initiating a pivotal trial in Behcet’s disease, which could begin by year-end 2011, pending regulatory feedback.
Week Ahead in Life Sciences
Wedbush Securities said that among the companies it covered in Life Sciences this week Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) are reporting earnings.
Cash Runway Expected for Xoma Through Start of Phase 3 Behcet's Uveitis Study: Analyst
Wedbush Securities expects cash runway for XOMA Ltd. (NASDAQ: XOMA) through start of phase 3 Behcet’s Uveitis study by year-end 2011.
Seattle Genetics drug gets priority FDA review
The U.S. Food and Drug Administration will review a Seattle Genetics Inc experimental drug for two types of lymphoma on a priority basis, the company said on Monday.
